Best Dividend Aristocrats to Buy According to Hedge Funds


Between 1900 and 2000, dividends accounted for more than half of the S&P 500 Index’s average yearly total return. According to a survey by Post Oak Private Wealth Advisors, dividend stocks have a considerable positive impact on total return during bad markets. During bad market periods, dividends have accounted for almost 90% of the S&P 500’s total returns. In this circumstance, dividend aristocrats and other stable dividend-yielders may be the best alternative for an income investor. The dividend aristocrats are a group of publicly traded S&P 500 firms that have increased their dividends for at least 25 consecutive years. Every income investor’s portfolio should include PepsiCo, Inc. and Target Corporation.

Insider Monkey takes a look at the 10 best dividend aristocrats to buy according to hedge funds. Hedge funds ranked AT&T 10th on the list of the best dividend aristocrats to buy. In July, Kutgun Maral of RBC Capital assumed coverage of AT&T with a Sector Perform rating and a $30 price target. The headquarters of the corporation are in Atlanta, Georgia. Hedge funds put Medtronic Plc ninth on the list of the top dividend aristocrats to buy. Cardiovascular, Neuroscience, Medical-Surgical, and Diabetes are the four segments through which the corporation operates. Hedge funds put Exxon Mobil Corporation eighth on the list of the top dividend aristocrats to buy. The firm looks for crude oil and natural gas in the United States and around the world. Crude oil, natural gas, and petroleum products are transported, traded, produced, and sold. Hedge funds rate Becton, Dickinson and Company seventh among the top dividend aristocrats to purchase. Barclays analyst Travis Steed commenced coverage of Becton’s shares with an Equal Weight recommendation in May. Hedge funds put Abbott Laboratories sixth on the list of the top dividend aristocrats to buy. Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices are the company’s segments. Abbott Laboratories’ price target was boosted by Wells Fargo in July. For more details, click 10 Best Dividend Aristocrats to Buy According to Hedge Funds.